Article | October 19, 2023

Leveraging Technology And Expert Clinician Review To Enhance Risk Detection In Neuroscience Studies

Source: Premier Research

By Andreas Schreiner and Adam Simmons


The leading cause of trial failure across all indications has consistently been the inability to prove efficacy. A study analyzing 640 Phase 3 trials involving novel therapeutics found that 54% of them failed during clinical development, with over half (57%) failing due to insufficient efficacy. In the realm of neuroscience indications, an alarming 85% of late-phase studies falter, largely attributed to challenges like subjective endpoints, patient and disease variability, rater inconsistencies, and substantial placebo response rates, making it challenging to detect treatment effects.

Neuroscience therapy developers must proactively adopt a strategy to improve data quality and assess responses by strengthening risk and signal detection. In this blog, the authors explore how a combination of technology and expert clinician review can bolster risk and signal detection in neuroscience studies.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Tech Leader? Subscribe today.

Subscribe to Clinical Tech Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Tech Leader